Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 19/20 | 0.56 |
| ▸ | FNTB | P49356 | 19/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 17/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5551495 | 0.86 | FNTA (0.50) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7581857 | 0.83 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL7685251 | 0.77 | FNTA (0.61) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL3499080 | 0.76 | CYP19A1 (0.42) | — | |
| SCHEMBL7528653 | 0.75 | FNTA (0.63) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7665146 | 0.74 | FNTA (0.73) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7592794 | 0.72 | FNTA (0.67) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7683462 | 0.72 | FNTA (0.61) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7684988 | 0.71 | FNTA (0.61) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL7682385 | 0.71 | FNTA (0.61) | FNTAFNTBPGGT1BCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | FNTA 19/4885FNTB 24/4885PGGT1B 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.